

Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

Ioanna Gazouli¹

¹ 1st Medical Oncology Department, Metropolitan Hospital, Athens, Greece

Potential competing interests: No potential competing interests to declare.

I found the present paper very intriguing indeed. The problematic is well presented, and the authors' arguments are adequately supported by statistical evidence.

Concerns are raised in a thorough, comprehensive, and well-structured manner.

In general, I think this paper is a very good attempt to look into the risks of substituting established treatments with novel ones, without considering statistical and other research artifacts, thus affecting treatment algorithms without adequately established benefits for patients treated.

Considering the powerful, yet underestimated effect of patients censored, and assuming some of them may have been lost to follow-up due to treatment toxicity, maybe it would be interesting to look into the event-free survival, with events including disease progression and unacceptable toxicity/death, in order to investigate the actual benefit of sotorasib over docetaxel, if any.

In conclusion, a well-established and intriguing paper.